Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 10;8(2):140.
doi: 10.3390/cells8020140.

Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus

Yasuo Nagafuchi  1 , Hirofumi Shoda  2 , Keishi Fujio  3
Affiliations
Review

Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus

Yasuo Nagafuchi et al. Cells. .

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder with a wide range of clinical symptoms. Enormous progress has been made in the immunological and genetic understanding of SLE. However, the biology of disease heterogeneity in SLE has remained largely unexplored. Human immune profiling studies, helped by recent technological advances especially in single-cell and "omics" analyses, are now shedding light on the cellular and molecular basis of clinical symptoms and disease flares in individual patients. Peripheral blood immunophenotyping analysis with flow cytometry or mass cytometry are identifying responsible cell subsets and markers characteristic of disease heterogeneity. Transcriptome analysis is discovering molecular networks responsible for disease activity, disease subtype and future relapse. In this review, we summarize recent advances in the immune profiling analysis of SLE patients and discuss how they will be used for future precision medicine.

Keywords: immune profiling; precision medicine; single-cell analysis; systemic lupus erythematosus; transcriptome.

PubMed Disclaimer

Conflict of interest statement

KF received financial support or fees from Astellas, BMS, Daiichi-Sankyo, Mitsubishi Tanabe, Pfizer, Ayumi, Takeda, Chugai, Eisai, Taisho Toyama, UCB, Janssen, Eli Lilly and NIPPON KAYAKU. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Stratified treatment of systemic lupus erythematosus (SLE) patients based on prognostic and predictive biomarkers.
See this image and copyright information in PMC

References

    1. Wahren-Herlenius M., Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382:819–831. doi: 10.1016/S0140-6736(13)60954-X. - DOI - PubMed
    1. Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–1888. doi: 10.1016/S0140-6736(14)60128-8. - DOI - PubMed
    1. Zandman-Goddard G., Solomon M., Rosman Z., Peeva E., Shoenfeld Y. Environment and lupus-related diseases. Lupus. 2012;21:241–250. doi: 10.1177/0961203311426568. - DOI - PubMed
    1. Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N., Costa F.R.C., Tiniakou E., Greiling T., Ruff W., et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359:1156–1161. doi: 10.1126/science.aar7201. - DOI - PMC - PubMed
    1. Tsokos G.C., Lo M.S., Costa Reis P., Sullivan K.E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2016;12:716–730. doi: 10.1038/nrrheum.2016.186. - DOI - PubMed

MeSH terms